Oncology Drug Value Tools From NCCN, ASCO To Get Real-World Testing
This article was originally published in The Pink Sheet Daily
Executive Summary
Officials from oncology professional organizations discuss next steps in the development of their frameworks for valuing oncology drugs.
You may also be interested in...
ASCO's Richard Schilsky On State-of-the-Art Oncology Trials
ASCO's chief medical officer Richard Schilsky discusses innovative clinical trial designs in oncology, challenges facing developers of cancer combination therapies and future developments for the society's value frameworks.
As Drug Value Frameworks Gain Traction, Patients Seek More Input
'Patients are ready and willing to have conversations' about trade-offs, National Health Council's Perfetto says.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.